Sucampo Pharmaceuticals, Inc. 4
4 · Sucampo Pharmaceuticals, Inc. · Filed Jan 23, 2014
Insider Transaction Report
Form 4
Dolecek Gayle R
DirectorVP of Research & Development
Transactions
- Exercise/Conversion
Common Stock
2014-01-13$4.41/sh+9,066$39,981→ 9,066 total - Sale
Common Stock
2014-01-13$9.21/sh−9,066$83,498→ 0 total - Exercise/Conversion
Employee Stock Option (Right to Buy)
2014-01-13−9,066→ 323,634 totalExercise: $4.41Exp: 2021-05-02→ Common Stock (9,066 underlying)
Footnotes (2)
- [F1]The sales reported in this Form 4 were effected pursuant to a Rule10b5-1 trading plan adopted by the reporting person on June 13, 2013
- [F2]5,000 exercisable 5/2/2012; 4,066 exercisable 5/2/2013